Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Zoetis
ZTS
Zoetis
Simparica Trio And Global Animal Demand Will Transform Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 15 Analysts
Published
10 Aug 25
Updated
20 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$230.00
32.7% undervalued
intrinsic discount
20 Aug
US$154.79
1Y
-15.0%
7D
-0.6%
Loading
1Y
-15.0%
7D
-0.6%
Author's Valuation
US$230.0
32.7% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$230.0
32.7% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
11b
2014
2017
2020
2023
2025
2026
2028
Revenue US$11.4b
Earnings US$3.4b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
5.34%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$3.37b
Earnings '28
x
34.88x
PE Ratio '28
=
US$117.60b
Market Cap '28
US$117.60b
Market Cap '28
/
420.08m
No. shares '28
=
US$279.94
Share Price '28
US$279.94
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$229.96
Fair Value '25